NASDAQ:SGMO Sangamo Therapeutics (SGMO) Stock Price, News & Analysis $0.46 -0.03 (-5.33%) Closing price 04:00 PM EasternExtended Trading$0.46 0.00 (-0.42%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sangamo Therapeutics Stock (NASDAQ:SGMO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sangamo Therapeutics alerts:Sign Up Key Stats Today's Range$0.42▼$0.4650-Day Range$0.43▼$0.6052-Week Range$0.41▼$3.18Volume8.37 million shsAverage Volume6.59 million shsMarket Capitalization$106.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingModerate Buy Company Overview Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. Read More Sangamo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreSGMO MarketRank™: Sangamo Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 633rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSangamo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Sangamo Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sangamo Therapeutics are expected to grow in the coming year, from ($0.46) to ($0.26) per share.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.02% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 3.39%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.02% of the outstanding shares of Sangamo Therapeutics have been sold short.Short Interest Ratio / Days to CoverSangamo Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sangamo Therapeutics has recently decreased by 3.39%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment-0.43 News SentimentSangamo Therapeutics has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Sangamo Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for SGMO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Sangamo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.10% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions56.93% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sangamo Therapeutics' insider trading history. Receive SGMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Stock News HeadlinesSangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call TranscriptAugust 8 at 3:03 PM | seekingalpha.comSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial ResultsAugust 7 at 4:01 PM | globenewswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 8 at 2:00 AM | The Oxford Club (Ad)Sangamo Therapeutics (SGMO) Projected to Post Earnings on ThursdayAugust 6 at 2:25 AM | americanbankingnews.comSangamo Therapeutics Announces Second Quarter 2025 Earnings CallJuly 31, 2025 | globenewswire.comContrasting Inovio Pharmaceuticals (NASDAQ:INO) and Sangamo Therapeutics (NASDAQ:SGMO)July 31, 2025 | americanbankingnews.comSangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene TherapyJuly 25, 2025 | msn.comH.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy DataJuly 3, 2025 | msn.comSee More Headlines SGMO Stock Analysis - Frequently Asked Questions How have SGMO shares performed this year? Sangamo Therapeutics' stock was trading at $1.02 at the start of the year. Since then, SGMO shares have decreased by 55.2% and is now trading at $0.4569. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company had revenue of $18.31 million for the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative trailing twelve-month return on equity of 284.27%. Read the conference call transcript. Who are Sangamo Therapeutics' major shareholders? Top institutional investors of Sangamo Therapeutics include Geode Capital Management LLC (1.00%), Golden State Equity Partners (0.17%), Wealth Management Associates Inc. (0.13%) and Sanders Morris Harris LLC (0.08%). View institutional ownership trends. How do I buy shares of Sangamo Therapeutics? Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Intel (INTC), MSP Recovery (LIFW), abrdn Asia-Pacific Income Fund (FAX) and Tesla (TSLA). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:SGMO CIK1001233 Webwww.sangamo.com Phone(510) 970-6000Fax510-236-8951Employees480Year Founded1995Price Target and Rating Average Price Target for Sangamo Therapeutics$4.50 High Price Target$10.00 Low Price Target$2.00 Potential Upside/Downside+884.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.94 million Net Margins-124.61% Pretax Margin-124.84% Return on Equity-345.98% Return on Assets-79.86% Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual Sales$57.80 million Price / Sales1.84 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book4.15Miscellaneous Outstanding Shares233,170,000Free Float223,607,000Market Cap$106.54 million OptionableOptionable Beta1.18 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:SGMO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.